Halozyme Therapeutic (HALO) 9.94 $HALO
Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20
PR Newswire - Tue Jul 26, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Eisai Inc. has dosed the first patient in a collaborative phase 1b/2 clinical trial to assess whether Eisai's eribulin mesylate (HALAVEN®) in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) can improve overall response rate (ORR) - the proportion of women that have a predefined reduction in tumor burden - as compared with eribulin alone as a therapy in women with advanced or metastatic, High-Hyaluronan (HA) HER2-negative breast cancer.
HALO: 9.94 (+0.17)
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA
PR Newswire - Mon Jul 25, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial evaluating its investigational new drug, PEGPH20, in combination with KEYTRUDA (pembrolizumab) in patients with advanced non-small cell lung and gastric cancers under a revised clinical protocol.
HALO: 9.94 (+0.17)
Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance
PR Newswire - Wed Jun 08, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has entered into an agreement with Oxford Finance LLC and Silicon Valley Bank to refinance its existing senior secured loan facility.
HALO: 9.94 (+0.17)
Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20
PR Newswire - Sat Jun 04, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced results from a final analysis of 135 metastatic pancreatic cancer patients who were treated in Stage One of HALO 109-202, a phase 2 clinical study of its investigational new drug PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine (PAG arm) as compared to ABRAXANE and gemcitabine alone (AG arm).
HALO: 9.94 (+0.17)
Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference
PR Newswire - Tue May 17, 3:15PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2016 Global Health Care Conference in New York, on Tuesday, May 24 at 2:30 p.m. ET/11:30 a.m. PT. Laurie Stelzer, chief financial officer, will provide a corporate overview.
HALO: 9.94 (+0.17)
Halozyme Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 3:37PM CDT
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $19.8 million in its first quarter.
HALO: 9.94 (+0.17)
Halozyme Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 09, 3:05PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, which included an increase in revenue of 128 percent from the prior-year period and a net loss of $19.8 million, or $0.16 per share, compared to a net loss in the first quarter of 2015 of $15.1 million, or $0.12 per share.
HALO: 9.94 (+0.17)
The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma
Zacks Equity Research - Zacks Investment Research - Mon May 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma
HALO: 9.94 (+0.17), KITE: 56.63 (+2.11), INCY: 90.21 (+2.09), HZNP: 19.29 (-0.33), JUNO: 30.93 (+1.02)
Biotech Stocks Reporting on May 9: INCY, HZNP, JUNO & More
Kanchan Khanna - Zacks Investment Research - Fri May 06, 8:52AM CDT
What's in store for biotech stocks Juno, Incyte and others when they report their first-quarter results on May 9?
HALO: 9.94 (+0.17), KITE: 56.63 (+2.11), MDCO: 39.11 (+0.22), INCY: 90.21 (+2.09), HZNP: 19.29 (-0.33), AMGN: 172.03 (+0.75), JUNO: 30.93 (+1.02)
Halozyme Therapeutics Shares Up 31.1% Since SmarTrend's Buy Recommendation (HALO)
Comtex SmarTrend(R) - Fri Apr 22, 1:01PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on March 1st, 2016 at $9.07. In approximately 2 months, Halozyme Therapeutics has returned 31.11% as of today's recent price of $11.89.
HALO: 9.94 (+0.17)
Halozyme to Host First Quarter 2016 Financial Results Conference Call
PR Newswire - Wed Apr 20, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter on Monday, May 9 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2016.
HALO: 9.94 (+0.17)
Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment
PR Newswire - Mon Apr 18, 3:01PM CDT
Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced preclinical data for the discovery and early development of two potential drug candidates, an immune checkpoint inhibitor targeting adenosine and a novel antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR).
HALO: 9.94 (+0.17)
Halozyme Therapeutics Up 21.8% Since SmarTrend Uptrend Call (HALO)
Comtex SmarTrend(R) - Thu Apr 07, 1:55PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on March 1st, 2016 at $9.07. In approximately 1 month, Halozyme Therapeutics has returned 21.79% as of today's recent price of $11.04.
HALO: 9.94 (+0.17)
Halozyme To Present Data From Five Preclinical Studies At American Association Of Cancer Research Annual Conference
PR Newswire - Thu Mar 17, 7:30AM CDT
Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present preclinical data from five studies at the American Association of Cancer Research (AACR) annual conference next month, including results from its ongoing research of lead investigational agent, PEGPH20, and two novel pipeline assets engineered for increased action in the tumor microenvironment. The AACR annual conference will take place April 17-20 in New Orleans.
HALO: 9.94 (+0.17)
Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine
PR Newswire - Wed Mar 16, 7:30AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.
HALO: 9.94 (+0.17)
Halozyme Appoints Jim Daly To Board Of Directors
PR Newswire - Mon Mar 07, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Jim Daly to its board of directors. Mr. Daly is a biopharmaceutical executive with 30 years of experience leading U.S. and global businesses.
HALO: 9.94 (+0.17)
Global Halozyme Therapeutics, Inc. Market Business Survey Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 7:59AM CST
'HALOZYME THERAPEUTICS, INC. - Product Pipeline Review - 2015', provides an overview of the HALOZYME THERAPEUTICS, INC.'s pharmaceutical research and development focus.
HALO: 9.94 (+0.17)
Shares of HALO Down 39.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 02, 5:58PM CST
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on January 11th, 2016 at $13.39. In approximately 3 weeks, Halozyme Therapeutics has returned 39.41% as of today's recent price of $8.11.
HALO: 9.94 (+0.17)
Halozyme To Host Fourth Quarter And 2015 Year-End Financial Results Conference Call
PR Newswire - Mon Feb 01, 3:30PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2015 on Monday, February 29 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the fourth quarter and year-ended December 31, 2015.
HALO: 9.94 (+0.17)
Halozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing
PR Newswire - Tue Jan 26, 3:05PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE(TM) products, received only from Halozyme's collaborations with Roche and Baxalta.
HALO: 9.94 (+0.17)
Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20
PR Newswire - Tue Jul 26, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Eisai Inc. has dosed the first patient in a collaborative phase 1b/2 clinical trial to assess whether Eisai's eribulin mesylate (HALAVEN®) in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) can improve overall response rate (ORR) - the proportion of women that have a predefined reduction in tumor burden - as compared with eribulin alone as a therapy in women with advanced or metastatic, High-Hyaluronan (HA) HER2-negative breast cancer.
HALO: 9.94 (+0.17)
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA
PR Newswire - Mon Jul 25, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial evaluating its investigational new drug, PEGPH20, in combination with KEYTRUDA (pembrolizumab) in patients with advanced non-small cell lung and gastric cancers under a revised clinical protocol.
HALO: 9.94 (+0.17)
Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance
PR Newswire - Wed Jun 08, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has entered into an agreement with Oxford Finance LLC and Silicon Valley Bank to refinance its existing senior secured loan facility.
HALO: 9.94 (+0.17)
Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20
PR Newswire - Sat Jun 04, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced results from a final analysis of 135 metastatic pancreatic cancer patients who were treated in Stage One of HALO 109-202, a phase 2 clinical study of its investigational new drug PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine (PAG arm) as compared to ABRAXANE and gemcitabine alone (AG arm).
HALO: 9.94 (+0.17)
Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference
PR Newswire - Tue May 17, 3:15PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2016 Global Health Care Conference in New York, on Tuesday, May 24 at 2:30 p.m. ET/11:30 a.m. PT. Laurie Stelzer, chief financial officer, will provide a corporate overview.
HALO: 9.94 (+0.17)
Halozyme Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 3:37PM CDT
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $19.8 million in its first quarter.
HALO: 9.94 (+0.17)
Halozyme Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 09, 3:05PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, which included an increase in revenue of 128 percent from the prior-year period and a net loss of $19.8 million, or $0.16 per share, compared to a net loss in the first quarter of 2015 of $15.1 million, or $0.12 per share.
HALO: 9.94 (+0.17)
The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma
Zacks Equity Research - Zacks Investment Research - Mon May 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma
HALO: 9.94 (+0.17), KITE: 56.63 (+2.11), INCY: 90.21 (+2.09), HZNP: 19.29 (-0.33), JUNO: 30.93 (+1.02)
Biotech Stocks Reporting on May 9: INCY, HZNP, JUNO & More
Kanchan Khanna - Zacks Investment Research - Fri May 06, 8:52AM CDT
What's in store for biotech stocks Juno, Incyte and others when they report their first-quarter results on May 9?
HALO: 9.94 (+0.17), KITE: 56.63 (+2.11), MDCO: 39.11 (+0.22), INCY: 90.21 (+2.09), HZNP: 19.29 (-0.33), AMGN: 172.03 (+0.75), JUNO: 30.93 (+1.02)
Halozyme Therapeutics Shares Up 31.1% Since SmarTrend's Buy Recommendation (HALO)
Comtex SmarTrend(R) - Fri Apr 22, 1:01PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on March 1st, 2016 at $9.07. In approximately 2 months, Halozyme Therapeutics has returned 31.11% as of today's recent price of $11.89.
HALO: 9.94 (+0.17)
Halozyme to Host First Quarter 2016 Financial Results Conference Call
PR Newswire - Wed Apr 20, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter on Monday, May 9 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2016.
HALO: 9.94 (+0.17)
Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment
PR Newswire - Mon Apr 18, 3:01PM CDT
Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced preclinical data for the discovery and early development of two potential drug candidates, an immune checkpoint inhibitor targeting adenosine and a novel antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR).
HALO: 9.94 (+0.17)
Halozyme Therapeutics Up 21.8% Since SmarTrend Uptrend Call (HALO)
Comtex SmarTrend(R) - Thu Apr 07, 1:55PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on March 1st, 2016 at $9.07. In approximately 1 month, Halozyme Therapeutics has returned 21.79% as of today's recent price of $11.04.
HALO: 9.94 (+0.17)
Halozyme To Present Data From Five Preclinical Studies At American Association Of Cancer Research Annual Conference
PR Newswire - Thu Mar 17, 7:30AM CDT
Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present preclinical data from five studies at the American Association of Cancer Research (AACR) annual conference next month, including results from its ongoing research of lead investigational agent, PEGPH20, and two novel pipeline assets engineered for increased action in the tumor microenvironment. The AACR annual conference will take place April 17-20 in New Orleans.
HALO: 9.94 (+0.17)
Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine
PR Newswire - Wed Mar 16, 7:30AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.
HALO: 9.94 (+0.17)
Halozyme Appoints Jim Daly To Board Of Directors
PR Newswire - Mon Mar 07, 8:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Jim Daly to its board of directors. Mr. Daly is a biopharmaceutical executive with 30 years of experience leading U.S. and global businesses.
HALO: 9.94 (+0.17)
Global Halozyme Therapeutics, Inc. Market Business Survey Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 7:59AM CST
'HALOZYME THERAPEUTICS, INC. - Product Pipeline Review - 2015', provides an overview of the HALOZYME THERAPEUTICS, INC.'s pharmaceutical research and development focus.
HALO: 9.94 (+0.17)
Shares of HALO Down 39.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 02, 5:58PM CST
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on January 11th, 2016 at $13.39. In approximately 3 weeks, Halozyme Therapeutics has returned 39.41% as of today's recent price of $8.11.
HALO: 9.94 (+0.17)
Halozyme To Host Fourth Quarter And 2015 Year-End Financial Results Conference Call
PR Newswire - Mon Feb 01, 3:30PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2015 on Monday, February 29 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the fourth quarter and year-ended December 31, 2015.
HALO: 9.94 (+0.17)
Halozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing
PR Newswire - Tue Jan 26, 3:05PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE(TM) products, received only from Halozyme's collaborations with Roche and Baxalta.
HALO: 9.94 (+0.17)
